CD4 Mimetic Small Molecules Targeting HIV gp120 Phe 43 Pocket
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to prevent and treat HIV infection are inadequate in targeting the early phase of HIV entry into host cells, particularly the interaction between HIV envelope glycoproteins and host cell receptors, due to the variability and flexibility of HIV envelope glycoproteins like gp120, which complicates the development of effective prophylactic and therapeutic agents.
Innovation Solution
Development of compounds that specifically bind to the Phe 43 pocket of the HIV gp120 glycoprotein, inducing conformational changes that inhibit HIV entry by mimicking the CD4 receptor, thereby preventing the virus from binding to host cell receptors and triggering irreversible changes in the viral envelope glycoproteins, leading to reduced infectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to bind to the Phe 43 pocket of gp120 to inhibit HIV entry, then the ability to block viral transmission is improved, but the complexity of designing effective compounds increases due to the variability and flexibility of HIV envelope glycoproteins
Solution Approach 1:
The compounds are designed to bind to the Phe 43 pocket of gp120 before the virus can bind to the CD4 receptor on host cells. This preliminary binding action prevents the conformational changes necessary for viral entry, effectively blocking transmission at an early stage. The compounds act as pre-blockers that occupy the critical binding site before the virus can engage with host cell receptors.
Solution Approach 2:
The compounds mimic the binding interface of the natural CD4 receptor by targeting the Phe 43 pocket, which is the key interaction site between CD4 and gp120. By copying the essential binding features of CD4 in a simplified small molecule format, the compounds can induce conformational changes in gp120 similar to those triggered by CD4 binding, thereby activating the virus in a controlled manner that leads to loss of infectivity.
2Reliability
If compounds induce conformational changes in gp120 to activate the virus, then the ability to inhibit transmission is improved, but the risk of triggering irreversible changes that could enhance infectivity increases
Solution Approach 1:
The compounds perform a preliminary activation of gp120 by binding to the Phe 43 pocket and inducing conformational changes similar to those caused by CD4 binding. This preliminary action triggers a cascade of structural changes that ultimately lead to the exposure of the fusion peptide and irreversible activation of the viral envelope, rendering the virus non-infectious before it can complete the entry process.
Solution Approach 2:
The compounds act as a cushioning mechanism by controlling the conformational changes in gp120 in a way that leads to a dead-end activated state. Instead of allowing the virus to proceed through normal entry pathways, the compounds guide the conformational changes toward an irreversible activated intermediate that cannot complete infection, thereby cushioning against the risk of enhancing infectivity.
3Ease of operation
If small molecules are used to target the Phe 43 pocket, then the ease of administration is improved, but the affinity and selectivity required to effectively compete with CD4 binding increases
Solution Approach 1:
The invention extracts the essential binding features of the large CD4 receptor into a simplified small molecule structure that can fit into the Phe 43 pocket. By taking out only the critical interaction elements needed to bind gp120 and induce conformational changes, the compounds achieve the desired effect with much smaller, more administrable molecules that do not require the full complexity of the natural receptor.
Solution Approach 2:
The compounds are designed with specific molecular parameters (size, shape, functional groups) that optimize their ability to bind to the Phe 43 pocket with high affinity and selectivity. By carefully adjusting these parameters, the compounds can effectively compete with CD4 binding despite their smaller size, achieving the necessary binding strength to trigger the desired conformational changes in gp120.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit HIV transmission and progression by inducing transient activated states in the viral envelope glycoproteins, resulting in rapid decay and loss of functional competence, thereby reducing the virus's ability to infect cells, even in the absence of the CD4 receptor.
Implementation Method 1
inducing conformational changes that inhibit HIV entry by mimicking the CD4 receptor
Implementation Method 2
inducing transient activated states in the viral envelope glycoproteins, resulting in rapid decay and loss of functional competence
Data Source
AI summary
The invention provides for compounds of formula I: wherein Z is absent or (CRARB)nW; each RA and RB is independently (i) H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, haloalkyl, each of which may be optionally substituted; (ii) OH, ORc, NH2, NHRc, NRcRc, SH, S(O)mRc; or (iii) RA and RB together form C(O); W is absent, C(O), C(O)O, C(O)NRcRc, O, S(O)m, or NRcRc; Y is an optionally substituted heterocyclic, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted aryl, or NRXRY; wherein Rx and Ry are each independently H, alkyl or aryl; X1 is selected from the group consisting of halogen, methyl, and hydroxyl; X2 is a halogen; each Rc is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which may be optionally substituted; m is O, 1, or 2; and n is 1, 2, 3, 4, 5, or 6; and pharmaceutically acceptable salts thereof.